77 related articles for article (PubMed ID: 23889174)
1. Stromal architecture and periductal decorin are potential prognostic markers for ipsilateral locoregional recurrence in ductal carcinoma in situ of the breast.
Van Bockstal M; Lambein K; Gevaert O; De Wever O; Praet M; Cocquyt V; Van den Broecke R; Braems G; Denys H; Libbrecht L
Histopathology; 2013 Oct; 63(4):520-33. PubMed ID: 23889174
[TBL] [Abstract][Full Text] [Related]
2. Thrombospondin 1 protein expression relates to good prognostic indices in ductal carcinoma in situ of the breast.
Rice AJ; Steward MA; Quinn CM
J Clin Pathol; 2002 Dec; 55(12):921-5. PubMed ID: 12461058
[TBL] [Abstract][Full Text] [Related]
3. Thymidine phosphorylase expression and stromal vascularity in ductal carcinoma in situ of the breast.
Teo NB; Shoker BS; Jarvis C; Sloane JP; Holcombe C
J Clin Pathol; 2003 Dec; 56(12):919-23. PubMed ID: 14645350
[TBL] [Abstract][Full Text] [Related]
4. Impact of the presence and quantity of ductal carcinoma in situ component on the outcome of invasive breast cancer.
Cedolini C; Bertozzi S; Londero AP; Seriau L; Andretta M; Agakiza D; Fongione S; Uzzau A; Risaliti A
Int J Clin Exp Pathol; 2015; 8(10):13304-13. PubMed ID: 26722534
[TBL] [Abstract][Full Text] [Related]
5. Microcalcification crystallography as a potential marker of DCIS recurrence.
Gosling SB; Arnold EL; Davies SK; Cross H; Bouybayoune I; Calabrese D; Nallala J; Pinder SE; Fu L; Lips EH; King L; Marks J; Hall A; Grimm LJ; Lynch T; Pinto D; Stobart H; Hwang ES; Wesseling J; Geraki K; Stone N; Lyburn ID; Greenwood C; Rogers KD;
Sci Rep; 2023 Jun; 13(1):9331. PubMed ID: 37291276
[TBL] [Abstract][Full Text] [Related]
6. Molecular classification and biomarkers of clinical outcome in breast ductal carcinoma in situ: Analysis of TBCRC 038 and RAHBT cohorts.
Strand SH; Rivero-Gutiérrez B; Houlahan KE; Seoane JA; King LM; Risom T; Simpson LA; Vennam S; Khan A; Cisneros L; Hardman T; Harmon B; Couch F; Gallagher K; Kilgore M; Wei S; DeMichele A; King T; McAuliffe PF; Nangia J; Lee J; Tseng J; Storniolo AM; Thompson AM; Gupta GP; Burns R; Veis DJ; DeSchryver K; Zhu C; Matusiak M; Wang J; Zhu SX; Tappenden J; Ding DY; Zhang D; Luo J; Jiang S; Varma S; Anderson L; Straub C; Srivastava S; Curtis C; Tibshirani R; Angelo RM; Hall A; Owzar K; Polyak K; Maley C; Marks JR; Colditz GA; Hwang ES; West RB
Cancer Cell; 2022 Dec; 40(12):1521-1536.e7. PubMed ID: 36400020
[TBL] [Abstract][Full Text] [Related]
7. Expression of immune-related genes and breast cancer recurrence in women with ductal carcinoma in situ.
Guerini-Rocco E; Bellerba F; Concardi A; Taormina SV; Cammarata G; Fumagalli C; Guerrieri-Gonzaga A; Macis D; Del Fiol Manna E; Balladore E; Cannone M; Veronesi P; Fusco N; Bonanni B; Viale G; Barberis M; Gandini S; Lazzeroni M
Eur J Cancer; 2024 May; 203():114063. PubMed ID: 38615592
[TBL] [Abstract][Full Text] [Related]
8. Pilot study demonstrating metabolic and anti-proliferative effects of in vivo anti-oxidant supplementation with N-Acetylcysteine in Breast Cancer.
Monti D; Sotgia F; Whitaker-Menezes D; Tuluc M; Birbe R; Berger A; Lazar M; Cotzia P; Draganova-Tacheva R; Lin Z; Domingo-Vidal M; Newberg A; Lisanti MP; Martinez-Outschoorn U
Semin Oncol; 2017 Jun; 44(3):226-232. PubMed ID: 29248134
[TBL] [Abstract][Full Text] [Related]
9. Ductal Carcinoma in Situ: Molecular Changes Accompanying Disease Progression.
Wilson GM; Dinh P; Pathmanathan N; Graham JD
J Mammary Gland Biol Neoplasia; 2022 Mar; 27(1):101-131. PubMed ID: 35567670
[TBL] [Abstract][Full Text] [Related]
10. Collagen Alignment as a Predictor of Recurrence after Ductal Carcinoma
Conklin MW; Gangnon RE; Sprague BL; Van Gemert L; Hampton JM; Eliceiri KW; Bredfeldt JS; Liu Y; Surachaicharn N; Newcomb PA; Friedl A; Keely PJ; Trentham-Dietz A
Cancer Epidemiol Biomarkers Prev; 2018 Feb; 27(2):138-145. PubMed ID: 29141852
[No Abstract] [Full Text] [Related]
11. Live-cell imaging of tumor proteolysis: impact of cellular and non-cellular microenvironment.
Rothberg JM; Sameni M; Moin K; Sloane BF
Biochim Biophys Acta; 2012 Jan; 1824(1):123-32. PubMed ID: 21854877
[TBL] [Abstract][Full Text] [Related]
12. Transition to invasive breast cancer is associated with progressive changes in the structure and composition of tumor stroma.
Risom T; Glass DR; Averbukh I; Liu CC; Baranski A; Kagel A; McCaffrey EF; Greenwald NF; Rivero-Gutiérrez B; Strand SH; Varma S; Kong A; Keren L; Srivastava S; Zhu C; Khair Z; Veis DJ; Deschryver K; Vennam S; Maley C; Hwang ES; Marks JR; Bendall SC; Colditz GA; West RB; Angelo M
Cell; 2022 Jan; 185(2):299-310.e18. PubMed ID: 35063072
[TBL] [Abstract][Full Text] [Related]
13. Epigenetic activation of SOX11 is associated with recurrence and progression of ductal carcinoma in situ to invasive breast cancer.
Treekitkarnmongkol W; Shah V; Kai K; Katayama H; Wong J; Ladha FA; Nguyen T; Menegaz B; Lu W; Yang F; Mino B; Tang X; Gagea M; Batra H; Raso MG; Wistuba II; Krishnamurthy S; Pinder SE; Sawyer EJ; Thompson AM; Sen S
Br J Cancer; 2024 May; ():. PubMed ID: 38760444
[TBL] [Abstract][Full Text] [Related]
14. Spatio-temporal modeling and live-cell imaging of proteolysis in the 4D microenvironment of breast cancer.
Ji K; Sameni M; Osuala K; Moin K; Mattingly RR; Sloane BF
Cancer Metastasis Rev; 2019 Sep; 38(3):445-454. PubMed ID: 31605250
[TBL] [Abstract][Full Text] [Related]
15. Ductal Carcinoma
Gorringe KL; Fox SB
Front Oncol; 2017; 7():248. PubMed ID: 29109942
[TBL] [Abstract][Full Text] [Related]
16. The role of endocrine treatment on the risk of developing an ipsilateral invasive breast cancer in hormone receptor positive patients with ductal carcinoma in situ.
Altundag K
Breast Cancer Res Treat; 2024 Feb; 204(1):189-190. PubMed ID: 38051408
[No Abstract] [Full Text] [Related]
17. HER2 expression should be routinely evaluated in DCIS to avoid under or overtreatment!
Garg N; Thorat MA
Oncoscience; 2023; 10():1-3. PubMed ID: 36733476
[No Abstract] [Full Text] [Related]
18. Breast cancer microenvironment and obesity: challenges for therapy.
Hillers-Ziemer LE; Kuziel G; Williams AE; Moore BN; Arendt LM
Cancer Metastasis Rev; 2022 Sep; 41(3):627-647. PubMed ID: 35435599
[TBL] [Abstract][Full Text] [Related]
19. Stromal Changes are Associated with High P4HA2 Expression in Ductal Carcinoma in Situ of the Breast.
Agahozo MC; van Bockstal M; Westenend PJ; Galant C; Lambein K; Reisenbichler E; Sinke R; Wong S; van Deurzen CHM
J Mammary Gland Biol Neoplasia; 2021 Dec; 26(4):367-375. PubMed ID: 35076865
[TBL] [Abstract][Full Text] [Related]
20. Plasma Levels of Decorin Increased in Patients during the Progression of Breast Cancer.
Hosoya T; Oda G; Nakagawa T; Onishi I; Hosoya T; Ishiguro M; Ishikawa T; Uetake H
J Clin Med; 2021 Nov; 10(23):. PubMed ID: 34884232
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
